Ingenol Mebutate
FDA-approved product (gel, topical), marketed as Ingenol Mebutate, Picato.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Actinic keratosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other chemotherapeutics
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D06BX02
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ingenol Mebutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
NCT02654769 · start 2015-02
Registered record
- Registry ID
- NCT02654769
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol Mebutate (Picato®); Generic Ingenol Mebutate; Vehicle Foam
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-02
- Completion
- 2015-09
- Enrolment
- 441
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol Mebutate (Picato®); Generic Ingenol Mebutate; Vehicle FoamPhasePhase 3Registry statusCompletedIngenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis
NCT02354391 · start 2015-01
Registered record
- Registry ID
- NCT02354391
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate Picato® and MAL PDT day 1, day 5; Ingenol mebutate Picato® day 2, 3, 4; MAL PDT day 5
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2015-01
- Completion
- 2019-12
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutate Picato® and MAL PDT day 1, day 5; Ingenol mebutate Picato® day 2, 3, 4; MAL PDT day 5PhasePhase 2Registry statusUnknownPMS to Evaluate the Safety and Efficacy of Picato® Gel
NCT02421471 · start 2014-09
Registered record
- Registry ID
- NCT02421471
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate 0.015 percent or 0.05 percent gel
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-09
- Completion
- 2018-01-19
- Enrolment
- 1,324
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutate 0.015 percent or 0.05 percent gelPhaseNot recordedRegistry statusCompletedThe Real Life Topical Field Treatment of Actinic Keratosis Study
NCT02362152 · start 2014-07
Registered record
- Registry ID
- NCT02362152
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate; 5-fluorouracil; Imiquimod; Diclofenac
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-07
- Completion
- 2015-12
- Enrolment
- 1,168
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutate; 5-fluorouracil; Imiquimod; DiclofenacPhaseNot recordedRegistry statusCompletedSafety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis
NCT02242747 · start 2014-05
Registered record
- Registry ID
- NCT02242747
- Conditions
- Actinic Keratosis
- Interventions
- ingenol mebutate; 5% 5-FU
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-05
- Completion
- 2014-08
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventioningenol mebutate; 5% 5-FUPhaseNot applicableRegistry statusCompletedPharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
NCT02124239 · start 2014-04
Registered record
- Registry ID
- NCT02124239
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2014-11
- Enrolment
- 79
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutatePhasePhase 1Registry statusCompletedTreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction
NCT04202445 · start 2014-04
Registered record
- Registry ID
- NCT04202445
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2016-02
- Enrolment
- 1,218
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutatePhaseNot recordedRegistry statusCompletedRisk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
NCT01926496 · start 2013-09-11
Registered record
- Registry ID
- NCT01926496
- Conditions
- Actinic Keratosis (AK)
- Interventions
- Ingenol Mebutate Gel, 0.015%; Imiquimod Cream, 5%
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-09-11
- Completion
- 2019-07-11
- Enrolment
- 485
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic Keratosis (AK)InterventionIngenol Mebutate Gel, 0.015%; Imiquimod Cream, 5%PhasePhase 4Registry statusCompletedHistological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
NCT01892137 · start 2013-07
Registered record
- Registry ID
- NCT01892137
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate gel 0.05%
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-07
- Completion
- 2014-05
- Enrolment
- 137
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutate gel 0.05%PhasePhase 1Registry statusCompletedSafety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
NCT02251652 · start 2013-04
Registered record
- Registry ID
- NCT02251652
- Conditions
- Actinic Keratoses
- Interventions
- Ingenol Mebutate; Cryotherapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-04
- Completion
- 2015-08
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosesInterventionIngenol Mebutate; CryotherapyPhasePhase 4Registry statusCompletedIngenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
NCT01836367 · start 2013-03
Registered record
- Registry ID
- NCT01836367
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol Mebutate 0.015%
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-03
- Completion
- 2013-08
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol Mebutate 0.015%PhasePhase 1Registry statusCompletedSafety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
NCT01803477 · start 2013-02
Registered record
- Registry ID
- NCT01803477
- Conditions
- Actinic Keratosis
- Interventions
- once daily for two consecutive days (Picato)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2013-02
- Completion
- 2013-12
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventiononce daily for two consecutive days (Picato)PhasePhase 1 / Phase 2Registry statusCompletedIngenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
NCT01600014 · start 2012-05
Registered record
- Registry ID
- NCT01600014
- Conditions
- Actinic Keratosis
- Interventions
- Ingenol mebutate gel, 0.015%; Vehicle gel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-05
- Completion
- 2014-02
- Enrolment
- 463
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionIngenol mebutate gel, 0.015%; Vehicle gelPhasePhase 3Registry statusCompletedA Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
NCT01541553 · start 2012-03
Registered record
- Registry ID
- NCT01541553
- Conditions
- Actinic Keratosis
- Interventions
- Cryotherapy; Vehicle; Ingenol metabute
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2013-07
- Enrolment
- 367
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionCryotherapy; Vehicle; Ingenol metabutePhasePhase 3Registry statusCompletedPEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
NCT01387711 · start 2011-08
Registered record
- Registry ID
- NCT01387711
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 (Ingenol mebutat Gel, 0.05 %)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-08
- Completion
- 2012-06
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionActinic KeratosisInterventionPEP005 (Ingenol mebutat Gel, 0.05 %)PhasePhase 1Registry statusCompleted